OptiBiotix Health PLC Director/PDMR Shareholding (1109G)

TIDMOPTI

RNS Number : 1109G

OptiBiotix Health PLC

25 March 2022

OptiBiotix Health plc

("OptiBiotix" or the "Company ")

PDMR Dealings

OptiBiotix Health p lc (AI M: OPTI), a life sciences busi ness d eveloping compou n ds to tackle obesity, high cholesterol, blood pressure and diabetes, ann o un ces that it was notified today of the following share purchases made by René Kamminga, CEO of Optibiotix Ltd:

 
 Date of transaction    Number of shares purchased   Price 
 23 March 2022          10,000                         40p 
                       ---------------------------  ------ 
 24 March 2022          2,656                          38p 
                       ---------------------------  ------ 
 

Following the above transactions, Mr Kamminga is interested in 55,844 ordinary shares in the Company, representing 0.06 per cent. of the Company's issued share capital.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

 
 OptiBiotix Health plc                                   www.optibiotix.com 
 Stephen O'Hara, Chief Executive                 Contact via Walbrook below 
 
 
 Cairn Financial Advisers LLP (NOMAD)                    Tel: [phone] 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 Cenkos Securities plc (Broker)                          Tel: [phone] 
 Callum Davidson / Neil McDonald 
 Michael Johnson / Russell Kerr (Sales) 
 
 Walbrook PR Ltd                                         Mob: [phone] 
 Anna Dunphy 
 
 
 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1      Details of the person discharging managerial responsibilities/person 
         closely associated 
       -------------------------------------------------------------------------------------------- 
 a.     Name                                     René Kamminga 
       ---------------------------------------  --------------------------------------------------- 
 2      Reason for notification 
       ---------------------------------------  --------------------------------------------------- 
 a.     Position/Status                          PDMR 
       ---------------------------------------  --------------------------------------------------- 
 b.     Initial notification/                    Initial Notification 
         Amendment 
       ---------------------------------------  --------------------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       -------------------------------------------------------------------------------------------- 
 a.     Name                                     OptiBiotix Health Plc 
       ---------------------------------------  --------------------------------------------------- 
 b.     LEI                                      213800UKYQFT941QHS14 
       ---------------------------------------  --------------------------------------------------- 
 4      Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions have 
         been conducted 
       -------------------------------------------------------------------------------------------- 
 a.     Description of                           Ordinary shares of 2p each 
         the financial 
         instrument, type 
         of instrument 
                                                  ISIN: GB00BP0RTP38 
         Identification 
         Code 
       ---------------------------------------  --------------------------------------------------- 
 b.     Nature of the                            Purchase of 12,656 ordinary shares in the 
         transaction                              Company 
       ---------------------------------------  --------------------------------------------------- 
 
 c.     Price(s) and volume(s)                           Price(s) per           Volume(s) 
                                                          share 
       ---------------------------------------          --------------------- 
                                                         40p                    10,000 
                                                          38p                    2,656 
                                                        ---------------------  ---------------- 
 
 d.          Aggregated information 
               *    Volume                         12,656 
                                                   Average price of 39.6p 
 
               *    Price 
       ---------------------------------------  --------------------------------------------------- 
 e.     Date of the transaction                  23 and 24s March 2022 
       ---------------------------------------  --------------------------------------------------- 
 f.     Place of the transaction                 London Stock Exchange, AIM 
       ---------------------------------------  --------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSELFLIEESEDD

(END) Dow Jones Newswires

March 25, 2022 10:36 ET (14:36 GMT)